Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
Objectives: Investigate trends over time and predictors of malignancies among children and young people with HIV. Design: Pooled data from 17 cohorts in 15 countries across Europe and Thailand. Methods: Individuals diagnosed with HIV and presenting to paediatric care less than 18 years of age were included. Time at risk began at birth for children with documented vertically acquired HIV, and from first HIV-care visit for others. Children were followed until death, loss-to-follow-up, or last visit in paediatric or adult care (where data after transfer to adult care were available). Rates of reported malignancies were calculated overall and for AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (NADM) separately. Risk factors for any malignancy were explored using Poisson regression, and for mortality following a malignancy diagnosis using Cox regression. Results: Among 9632 individuals included, 140 (1.5%) were ever diagnosed with a malignancy, of which 112 (80%) were ADM. Overall, the rate of any malignancy was 1.18 per 1000 person-years; the rate of ADM decreased over time whereas the rate of NADM increased. Male sex, being from a European cohort, vertically acquired HIV, current severe immunosuppression, current viral load greater than 400 copies/ml, older age, and, for those not on treatment, earlier calendar year, were risk factors for a malignancy diagnosis. Fifty-eight (41%) individuals with a malignancy died, a median 2.4 months (IQR 0.6-8.8) after malignancy diagnosis. Conclusion: The rate of ADM has declined since widespread availability of combination ART, although of NADM, there was a small increase. Mortality following a malignancy was high, warranting further investigation.
Malignancies among children and young people with HIV in Western and Eastern Europe and Thailand the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) study group
Chappell E.;Turkova A.;Goetghebuer T.;Jackson C.;Chiappini E.;Galli L.;Gingaras C.;Judd A.;Spoulou V.;Lisi C.;Ansone S.;Wolfs T.;Marczynska M.;Ene L.;Plotnikova Y.;Voronin E.;Samarina A.;Jourdain G.;Ngo-Giang-Huong N.;Fortuny C.;Navarro M. L.;Ramos J. T.;Naver L.;Crisinel P. -A.;Bailey H.;Malyuta R.;Volokha A.;Bamford A.;Crichton S.;Foster C.;Thorne C.;Collins I. J.;Giaquinto C.;Gibb D. M.;Critchton S.;Duff C.;Goodall R.;Gomezpena D.;Lundin R.;Mangiarini L.;Milanzi E.;Nardone A.;Hainaut M.;Van der Kelen E.;Delforge M.;de Martino M.;Tovo P. A.;Gabiano C.;Carloni I.;Larovere D.;Baldi F.;Miniaci A.;Pession A.;Badolato R.;Panto G.;Anastasio E.;Montagnani C.;Venturini E.;Bianchi L.;Allodi A.;Di Biagio A.;Grignolo S.;Giacomet V.;Marchisio P.;Banderali G.;Tagliabue C.;Cellini M.;Bruzzese E.;Di Costanzo P.;Lo Vecchio A.;Dona' D.;Rampon O.;Romano A.;Dodi I.;Esposito S.;Zuccaro V.;Zanaboni D.;Consolini R.;Bernardi S.;Genovese O.;Cristiano L.;Mazza A.;Garazzino S.;Mignone F.;Silvestro E.;Portelli V.;Pajkrt D.;Scherpbier H. J.;Weijsenfeld A. M.;de Boer C. G.;Jurriaans S.;Back N. K. T.;Zaaijer H. L.;Berkhout B.;Cornelissen M. T. E.;Schinkel C. J.;Wolthers K. C.;Fraaij P. L. A.;van Rossum A. M. C.;Vermont C. L.;van der Knaap L. C.;Visser E. G.;Boucher C. A. B.;Koopmans M. P. G.;van Kampen J. J. A.;Pas S. D.;Henriet S. S. V.;van de Flier M.;van Aerde K.;Strik-Albers R.;Rahamat-Langendoen J.;Stelma F. F.;Scholvinck E. H.;de Groot-De Jonge H.;Niesters H. G. M.;van Leer-Buter C. C.;Knoester M.;Bont L. J.;Geelen S. P. M.;Wolfs T. F. W.;Nauta N.;Schuurman R.;Verduyn-Lunel F.;Wensing A. M. J.;Reiss P.;Zaheri S.;Bezemer D. O.;van Sighem A. I.;Smit C.;Wit F. W. M. N.;Hillebregt M.;de Jong A.;Woudstra T.;Bergsma D.;Grivell S.;Meijering R.;Raethke M.;Rutkens T.;de Groot L.;van den Akker M.;Bakker Y.;Bezemer M.;El Berkaoui A.;Geerlinks J.;Koops J.;Kruijne E.;Lodewijk C.;Lucas E.;van der Meer R.;Munjishvili L.;Paling F.;Peeck B.;Ree C.;Regtop R.;Ruijs Y.;van de Sande L.;Schoorl M.;Schnorr P.;Tuijn E.;Veenenberg L.;van der Vliet S.;Wisse A.;Witte E. C.;Tuk B.;Marczynska M.;Popielska J.;Pokorska-Spiewak M.;Oldakowska A.;Zawadka K.;Coupland U.;Doroba M.;Miloenko M.;Labutina S.;Soler-Palacin P.;Frick M. A.;Perez-Hoyos S.;Mur A.;Lopez N.;Mendez M.;Mayol L.;Vallmanya T.;Calavia O.;Garcia L.;Coll M.;Pineda V.;Rius N.;Rovira N.;Duenas J.;Noguera-Julian A.;Mellado M. J.;Escosa L.;Hortelano M. G.;Sainz T.;Gonzalez-Tome M. I.;Rojo P.;Blazquez D.;Prieto L.;Guillen S.;Saavedra J.;Santos M.;Munoz M. A.;Ruiz B.;Fernandez C.;Phee M.;de Ory S. J.;Alvarez S.;Roa M. A.;Beceiro J.;Martinez J.;Badillo K.;Apilanez M.;Pocheville I.;Garrote E.;Colino E.;Sirvent J. G.;Garzon M.;Roman V.;Montesdeoca A.;Mateo M.;Munoz M. J.;Angulo R.;Neth O.;Falcon L.;Terol P.;Santos J. L.;Moreno D.;Lendinez F.;Grande A.;Romero F. J.;Perez C.;Lillo M.;Losada B.;Herranz M.;Bustillo M.;Guerrero C.;Collado P.;Couceiro J. A.;Perez A.;Piqueras A. I.;Breton R.;Segarra I.;Gavilan C.;Jareno E.;Montesinos E.;Dapena M.;Alvarez C.;Andres A. G.;Marugan V.;Ochoa C.;Alfayate S.;Menasalvas A. I.;de Miguel E.;Soeria-Atmadja S.;Belfrage E.;Hagas V.;Aebi-Popp K.;Anagnostopoulos A.;Asner S.;Battegay M.;Baumann M.;Bernasconi E.;Boni J.;Braun D. L.;Bucher H. C.;Calmy A.;Cavassini M.;Ciuffi A.;Duppenthaler A.;Dollenmaier G.;Egger M.;Elzi L.;Fehr J.;Fellay J.;Francini K.;Furrer H.;Fux C. A.;Grawe C.;Gunthard H. F.;Haerry D.;Hasse B.;Hirsch H. H.;Hoffmann M.;Hosli I.;Huber M.;Kahlert C. R.;Kaiser L.;Keiser O.;Klimkait T.;Kottanattu L.;Kouyos R. D.;Kovari H.;Ledergerber B.;Martinetti G.;Martinez de Tejada B.;Marzolini C.;Metzner K. J.;Muller N.;Nicca D.;Paioni P.;Pantaleo G.;Perreau M.;Polli Ch.;Rauch A.;Rudin C.;Scherrer A. U.;Schmid P.;Speck R.;Stockle M.;Tarr P.;Thanh Lecompte M.;Trkola A.;Vernazza P.;Wagner N.;Wandeler G.;Weber R.;Wyler C. A.;Yerly S.;Wannarit P.;Techakunakorn P.;Hansudewechakul R.;Wanchaitanawong V.;Theansavettrakul S.;Nanta S.;Ngampiyaskul C.;Phanomcheong S.;Hongsiriwon S.;Karnchanamayul W.;Kwanchaipanich R.;Kanjanavanit S.;Kamonpakorn N.;Nantarukchaikul M.;Layangool P.;Mekmullica J.;Lucksanapisitkul P.;Watanayothin S.;Lertpienthum N.;Warachit B.;Hanpinitsak S.;Potchalongsin S.;Thanasiri P.;Krikajornkitti S.;Attavinijtrakarn P.;Srirojana S.;Bunjongpak S.;Puangsombat A.;Na-Rajsima S.;Ananpatharachai P.;Akarathum N.;Lawtongkum W.;Kheunjan P.;Suriyaboon T.;Saipanya A.;Than-In-At K.;Jaisieng N.;Suaysod R.;Chailoet S.;Naratee N.;Kawilapat S.;Kaleeva T.;Baryshnikova Y.;Soloha S.;Bashkatova N.;Raus I.;Glutshenko O.;Ruban Z.;Prymak N.;Kiseleva G.;Lyall H.;Butler K.;Doerholt K.;Doherty C.;Harrison I.;Kenny J.;Klein N.;Letting G.;McMaster P.;Murau F.;Nsangi E.;Prime K.;Riordan A.;Shackley F.;Shingadia D.;Storey S.;Tudor-Williams G.;Welch S.;Cook C.;Dobson D.;Fairbrother K.;Le Prevost M.;Van Looy N.;Peters H.;Francis K.;Thrasyvoulou L.;Fidler K.;Bernatoniene J.;Manyika F.;Sharpe G.;Subramaniam B.;Hague R.;Price V.;Flynn J.;Cardoso A.;Abou-Rayyah M.;Yeadon S.;Segal S.;Hawkins S.;Dowie M.;Bandi S.;Percival E.;Eisenhut M.;Duncan K.;Anguvaa L.;Wren L.;Flood T.;Pickering A.;Murphy C.;Daniels J.;Lees Y.;Thompson F.;Williams A.;Williams B.;Pope S.;Libeschutz S.;Cliffe L.;Southall S.;Freeman A.;Freeman H.;Christie S.;Gordon A.;Hague D. R.;Clarke L.;Jones L.;Brown L.;Greenberg M.;Benson C.;Ibberson L.;Patel S.;Hancock J.;Sharland M.;Lyall E. G. H.;Seery P.;Kirkhope N.;Raghunanan S.;Callaghan A.;Bridgwood A.;Evans J.;Blake E.;Yannoulias A.
2021
Abstract
Objectives: Investigate trends over time and predictors of malignancies among children and young people with HIV. Design: Pooled data from 17 cohorts in 15 countries across Europe and Thailand. Methods: Individuals diagnosed with HIV and presenting to paediatric care less than 18 years of age were included. Time at risk began at birth for children with documented vertically acquired HIV, and from first HIV-care visit for others. Children were followed until death, loss-to-follow-up, or last visit in paediatric or adult care (where data after transfer to adult care were available). Rates of reported malignancies were calculated overall and for AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (NADM) separately. Risk factors for any malignancy were explored using Poisson regression, and for mortality following a malignancy diagnosis using Cox regression. Results: Among 9632 individuals included, 140 (1.5%) were ever diagnosed with a malignancy, of which 112 (80%) were ADM. Overall, the rate of any malignancy was 1.18 per 1000 person-years; the rate of ADM decreased over time whereas the rate of NADM increased. Male sex, being from a European cohort, vertically acquired HIV, current severe immunosuppression, current viral load greater than 400 copies/ml, older age, and, for those not on treatment, earlier calendar year, were risk factors for a malignancy diagnosis. Fifty-eight (41%) individuals with a malignancy died, a median 2.4 months (IQR 0.6-8.8) after malignancy diagnosis. Conclusion: The rate of ADM has declined since widespread availability of combination ART, although of NADM, there was a small increase. Mortality following a malignancy was high, warranting further investigation.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3449286
Citazioni
0
0
2
ND
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
